InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
The company’s foremost asset is the drug candidate cobitolimod, which is in the late stages of clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm.
In connection with the listing of the company’s shares, a new issue of shares of 250 MSEK was made. SEB Venture Capital, and Stiftelsen Industrifonden and NeoMed will continue to be long-term shareholders in InDex.
Trading in the company’s shares on Nasdaq First North commenced on 11 October 2016 under the trading symbol INDEX.